October 29, 2018 | Joanne Morrison
Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559
Contact Media Relations
Friday, October 11, 2019
In continuing efforts to find novel ways to kill cancer cells, researchers at the University of Maryland School of Medicine (UMSOM) have identified a new pathway that leads to the destruction of cancer cells. The new finding, published this week in the journal PNAS, could pave the way for the broader use of a class of anticancer drugs already on the market. These drugs, known as PARP inhibitors, are currently approved by the FDA to treat only a limited group of breast and ovarian cancers associated with BRCA gene mutations.
Wednesday, July 31, 2019
Inconsistent Reporting of Methodologies Makes Most Radiation Biology Studies Impossible to Replicate
Nearly 80 percent of radiation oncology studies funded by the National Institutes of Health involve investigating the effects that radiation has on tumor cells and healthy tissue in pre-clinical settings, such as experiments done in cell cultures or mice. A majority of these radiation biology studies, however, have serious flaws in how their irradiation methodology is described, which makes them very difficult to replicate, according to a new finding from the University of Maryland School of Medicine (UMSOM).
Tuesday, February 19, 2019
Dr. Robert C. Miller, National Leader in Radiation Oncology, Named New Medical Director of Maryland Proton Treatment Center
William F. Regine, MD, FACR, FACRO, The Isadore and Fannie Schneider Foxman Chair and Professor of Radiation Oncology at the University of Maryland School of Medicine (UMSOM), along with UMSOM Dean E. Albert Reece, MD, PhD, MBA, announced today that Robert C. Miller, MD, MBA, FASTRO a nationally-recognized radiation oncologist who currently serves as Vice Chair in the Department of Radiation Oncology at the Mayo Clinic, has been named Professor in the UMSOM Department of Radiation Oncology and Medical Director of the Maryland Proton Treatment Center (MPTC). He will begin his new position in April 2019.
Monday, October 08, 2018
High-Precision Proton Therapy More Effective in Treating Certain Cancers When Combined with Thermal Therapy
The Maryland Proton Treatment Center (MPTC) is now offering deep-tissue external thermal therapy in combination with high-precision proton-beam radiotherapy as a potential way to boost survival chances for certain cancer patients. MPTC is the only center in the world to offer these two treatments at the same facility, an advantage to patients because these therapies are typically given within an hour of each other.
Monday, September 24, 2018
University of Maryland School of Medicine Researchers to Present Original Research at Key Radiation Conference
The University of Maryland School of Medicine (UMSOM) announced that the Division of Translational Radiation Science (DTRS) will participate in the annual meeting of the Radiation Research Society (RRS) on September 23-26, 2018, in Chicago.
Thursday, June 07, 2018
Most Early-Stage Breast Cancer Patients with Intermediate Risk of Recurrence can Safely Avoid Chemotherapy
The majority of women with early-stage estrogen receptor (ER)-positive breast cancer, considered at intermediate risk of having their cancer recur based on a 21-gene test, can safely forgo treatment with chemotherapy, according to a large multicenter clinical study published in the New England Journal of Medicine.
Monday, May 14, 2018
Gov. Larry Hogan Recognizes Achievements of Sally B. Cheston, MD, of Central Maryland Radiation Oncology Center
Maryland Gov. Larry Hogan today recognized Sally B. Cheston, MD, an assistant professor of radiation oncology at the University of Maryland School of Medicine (UMSOM), for her efforts to bring the “latest state-of-the-art medicine” to Howard County as a leader of the Central Maryland Radiation Oncology Center (CMRO).
Tuesday, December 12, 2017
Stewart Greenebaum, a prominent business and civic leader in Baltimore who dedicated much of his philanthropic work to supporting cancer research, treatment and education, passed away on Sunday, December 10, 2017. He was 81.
Tuesday, August 15, 2017
Mother-Daughter Kayaking Team to Complete 300-Mile Trip in Baltimore to Honor Late UM SOM Scientist Dr. Angela Brodie
Patients who receive life-saving care from a physician or surgeon are often so grateful that they make generous gifts to medical schools and hospitals where they were treated.
Monday, August 07, 2017
In 2017, more than 315,000 women in the U.S. are expected to be diagnosed with breast cancer. More than 40,000 are expected to die in 2017 from the disease. Over the course of their lives, one in 8 women in this country will develop invasive breast cancer.
Wednesday, June 07, 2017
In Memoriam: Angela Hartley Brodie, Ph.D., Internationally Renowned Breast Cancer Researcher at University of Maryland School of Medicine
Angela Hartley Brodie, PhD, Professor Emeritus in the Department of Pharmacology at the University of Maryland School of Medicine, and an internationally recognized scientist whose groundbreaking cancer research is considered among the greatest advances in treating breast cancer, passed away of complications from Parkinson’s disease at her home in Fulton, MD. She was 82.
Thursday, November 10, 2016
More than 500 people saw leading cancer scientists discuss their cutting-edge work at the fourth annual University of Maryland School of Medicine (UM SOM) Festival of Science, a one-day celebration of research at the school held November 10, 2016 the SMC Campus Center. The conference, titled “Cancer Research: Translational Discoveries to Next Generation Treatments,” featured a range of UM SOM’s top cancer researchers, who are working on the front lines of science to unravel crucial problems involving cancer in its many forms.
Friday, January 15, 2016
University of Maryland School of Medicine (UM SOM) Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that researchers at the UM SOM have been selected as key contractors by the Biomedical Advanced Research and Development Authority (BARDA), for its Radiation Nuclear Animal Model Development program. BARDA is part of the Office of the Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (DHHS).